JP2024536719A5 - - Google Patents
Info
- Publication number
- JP2024536719A5 JP2024536719A5 JP2024514008A JP2024514008A JP2024536719A5 JP 2024536719 A5 JP2024536719 A5 JP 2024536719A5 JP 2024514008 A JP2024514008 A JP 2024514008A JP 2024514008 A JP2024514008 A JP 2024514008A JP 2024536719 A5 JP2024536719 A5 JP 2024536719A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg1
- amino acid
- acid sequence
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10202109667X | 2021-09-03 | ||
| SG10202109667X | 2021-09-03 | ||
| PCT/EP2022/074520 WO2023031435A1 (en) | 2021-09-03 | 2022-09-02 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536719A JP2024536719A (ja) | 2024-10-08 |
| JP2024536719A5 true JP2024536719A5 (cg-RX-API-DMAC10.html) | 2025-09-10 |
Family
ID=83438993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514008A Pending JP2024536719A (ja) | 2021-09-03 | 2022-09-02 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250122303A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4396238A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024536719A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240110556A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118541395A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202328191A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023031435A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260026009A (ko) | 2023-04-06 | 2026-02-25 | 허밍버드 바이오사이언스 피티이. 엘티디. | Her3 항원 결합 분자를 이용한 암의 치료 및 예방 |
| CN120446468B (zh) * | 2025-07-07 | 2025-09-26 | 美康生物科技股份有限公司 | 一种血清游离轻链检测试剂及检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US20160319253A1 (en) | 2013-12-19 | 2016-11-03 | National Cancer Center | Novel fusion genes as factors responsible for gastric cancer |
| JP7737220B2 (ja) | 2017-03-31 | 2025-09-10 | メルス ナムローゼ フェンノートシャップ | ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体 |
| CN111527103A (zh) | 2017-09-08 | 2020-08-11 | 科罗拉多大学董事会,法人团体 | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 |
| WO2019241893A2 (en) * | 2018-06-22 | 2019-12-26 | Crd Pharmaceuticals Inc | Anti-her3 antibody and uses thereof |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2022
- 2022-09-02 CN CN202280074014.0A patent/CN118541395A/zh active Pending
- 2022-09-02 US US18/688,576 patent/US20250122303A1/en active Pending
- 2022-09-02 TW TW111133471A patent/TW202328191A/zh unknown
- 2022-09-02 JP JP2024514008A patent/JP2024536719A/ja active Pending
- 2022-09-02 EP EP22776887.6A patent/EP4396238A1/en active Pending
- 2022-09-02 WO PCT/EP2022/074520 patent/WO2023031435A1/en not_active Ceased
- 2022-09-02 KR KR1020247010142A patent/KR20240110556A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548057A5 (cg-RX-API-DMAC10.html) | ||
| Zhan et al. | Digestive cancers: mechanisms, therapeutics and management | |
| JP2017503480A5 (cg-RX-API-DMAC10.html) | ||
| Power et al. | Advanced gastric cancer–slow but steady progress | |
| Monk et al. | Anti-angiogenesis agents in metastatic or recurrent cervical cancer | |
| Kuwada et al. | Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer | |
| RU2016125551A (ru) | Биспецифические антигенсвязывающие конструкции против her2 | |
| JP2022533957A5 (cg-RX-API-DMAC10.html) | ||
| IL270852A (en) | Molecules that bind at the site of egfr and c – met - fibronectin type iii | |
| JP2016505537A5 (cg-RX-API-DMAC10.html) | ||
| del Campo et al. | Update on novel therapeutic agents for cervical cancer | |
| Salati et al. | Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? | |
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| JP7441165B2 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 | |
| JP2013522237A5 (cg-RX-API-DMAC10.html) | ||
| JP2023512276A5 (cg-RX-API-DMAC10.html) | ||
| TW202537643A (zh) | 抗體-藥物結合物之用途 | |
| CN105087593A (zh) | 一种her2核酸适配体及其应用 | |
| JP2023539589A5 (cg-RX-API-DMAC10.html) | ||
| Zhang et al. | Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression | |
| JP2025520232A5 (cg-RX-API-DMAC10.html) | ||
| JP2024071393A5 (cg-RX-API-DMAC10.html) | ||
| JP2024531353A5 (cg-RX-API-DMAC10.html) | ||
| RU2015154985A (ru) | Способы лечения рака | |
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения |